Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

DNA-Based immunization for asthma.

D Broide1, E Raz

  • 1University of California San Diego, Department of Medicine, La Jolla, CA, USA. dbroide@ucsd.edu

International Archives of Allergy and Immunology
|May 4, 1999
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Outcomes of Preoperative Transophthalmic Artery Embolization of Meningiomas: A Systematic Review with a Focus on Embolization Agent.

AJNR. American journal of neuroradiology·2023
Same author

Tumor Embolization through Meningohypophyseal and Inferolateral Trunks is Safe and Effective.

AJNR. American journal of neuroradiology·2022
Same author

Microsurgical clipping versus newer endovascular techniques in treatment of unruptured anterior communicating artery-complex aneurysms: a meta-analysis and systematic review.

Neurosurgical review·2021
Same author

Arterial and Venous 3D Fusion AV-3D-DSA: A Novel Approach to Cerebrovascular Neuroimaging.

AJNR. American journal of neuroradiology·2021
Same author

<i>Reply</i>.

AJNR. American journal of neuroradiology·2021
Same author

Dural Venous Channels: Hidden in Plain Sight-Reassessment of an Under-Recognized Entity.

AJNR. American journal of neuroradiology·2020
Same journal

Differences in Reported Anaphylaxis Associated With Common Nonsteroidal Anti-inflammatory Drugs: A Pharmacovigilance Study.

International archives of allergy and immunology·2026
Same journal

Association of Serum Galectin-3 Binding Protein with Acute Exacerbation, Inflammation, and Airway Remodeling in Pediatric Asthma.

International archives of allergy and immunology·2026
Same journal

Effectiveness of a Provincial Law to Improve Epinephrine Use for Anaphylaxis in Schools in Alberta, Canada: A Pre-Post Study.

International archives of allergy and immunology·2026
Same journal

Rab27 a regulates dendritic cell immune tolerogenic capacity.

International archives of allergy and immunology·2026
Same journal

Burden of Hereditary Angioedema in Adults: Impact of Disease and Patient Characteristics.

International archives of allergy and immunology·2026
Same journal

Predictors of Treatment Response to Omalizumab in Children with Chronic Spontaneous Urticaria: A Real World Study.

International archives of allergy and immunology·2026
See all related articles

Immunostimulatory DNA sequences (ISS) effectively inhibit asthma symptoms like airway eosinophilia. A single dose 6 days before allergen exposure is most effective, but coadministration also shows benefits.

Area of Science:

  • Immunology
  • Allergy and Asthma Research

Background:

  • Immunostimulatory DNA sequences (ISS) with CpG motifs can reduce Th2-mediated airway inflammation in asthma models.
  • Asthma is characterized by Th2-mediated airway eosinophilia and bronchial hyperresponsiveness.

Purpose of the Study:

  • To optimize the timing and frequency of ISS intervention for inhibiting Th2 cytokine production and airway eosinophilia.
  • To evaluate different administration routes (systemic vs. mucosal) and timings (before or with antigen) of ISS.

Main Methods:

  • Utilized a mouse model of ovalbumin-induced eosinophilic airway inflammation.
  • Investigated ISS administration protocols varying in dose frequency, route, and timing relative to antigen challenge.

Main Results:

Related Experiment Videos

  • ISS administration induced Th1 cytokines (IFN-gamma) and suppressed Th2 cytokines (IL-5) and eosinophilia.
  • A single ISS dose 6 days prior to allergen challenge was most effective.
  • Mucosal and systemic ISS delivery demonstrated comparable efficacy in reducing airway eosinophilia and shifting immune response.

Conclusions:

  • Single-dose ISS administration 6 days before antigen inhalation is optimal for inhibiting airway eosinophilia.
  • ISS can be administered concurrently with antigen to significantly reduce eosinophilic inflammation.
  • ISS shows potential as a novel immunotherapy approach for allergen-based treatments.